Financial Data and Key Metrics Changes - SNDL reported net revenue of CAD 244 million for Q3 2025, reflecting a 3.1% increase year-over-year, driven primarily by the cannabis segments [7][10] - Gross profit reached CAD 64.2 million, a 1.9% increase year-over-year, despite CAD 3.9 million in non-cash inventory-related adjustments [8][9] - Free cash flow for the quarter was CAD 16.7 million, marking a CAD 7.5 million improvement compared to the same period last year, and achieving positive cumulative free cash flow of CAD 7.7 million for the first nine months of the year [10][13] Business Line Data and Key Metrics Changes - The liquor retail segment generated net revenue of CAD 139.4 million, a 3.6% year-over-year decline, while gross profit was CAD 36.7 million, a modest reduction of CAD 0.2 million [14][15] - Cannabis retail achieved net revenue of CAD 85 million, a record high with a 4.8% year-over-year growth, and gross profit of CAD 22.5 million, reflecting an 8.5% increase [16] - Cannabis operations reported net revenue of CAD 37.4 million, a 50% growth year-over-year, driven by edibles and international sales [17] Market Data and Key Metrics Changes - The cannabis retail segment saw a 3.6% increase in same-store sales, contributing to a 12 basis points gain in market share [19] - International sales reached CAD 4.2 million in Q3, with expectations for continued growth due to strong demand and reliability of supply [20][33] Company Strategy and Development Direction - SNDL is focused on growth, profitability, and enhancing its workforce, with plans to open five new cannabis stores and two new Wine & Beyond stores in Q4 [19][21] - The company aims to strengthen its competitive position in Canada while resolving ongoing litigation related to Sunstream restructurings, which are expected to provide exposure to dynamic medical markets [5][6] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of CAD 11.9 million in unfavorable non-cash items on the P&L, but emphasized operational improvements and cash generation as key indicators of business fundamentals [4][3] - The outlook for cannabis retail is mixed, with signs of market maturity in provinces like Alberta and Ontario, but opportunities for margin improvement remain [36][39] Other Important Information - SNDL has no debt and over CAD 240 million in unrestricted cash, providing a strong balance sheet to support growth initiatives [5] - The company is experiencing a significant increase in share-based compensation due to a 121% rise in share price during Q3 [9][12] Q&A Session Summary Question: Clarification on cannabis operations write-offs - Management confirmed CAD 3.9 million inventory adjustment impacting gross profit and CAD 2.7 million fixed asset impairment affecting operating income but not gross margin [25][27] Question: Growth drivers for sales to provincial boards - Management noted softness in third-party retail sales but continued growth in their own segment, with expectations for regaining momentum through new products and innovation [29][30] Question: International sales outlook - Management expressed optimism about international sales growth, with strong demand and increasing purchase orders anticipated for Q4 and beyond [32][33] Question: Update on 1CMPharm transaction regulatory approval - Management stated that the review process is ongoing, with no additional information available at this time [35] Question: Market opportunities in cannabis retail - Management indicated a shift towards maturity in the market, with expectations for low single-digit revenue growth moving forward, while also noting improvements in gross margin [36][39] Question: RISE rewards program performance - Management reported strong engagement from loyalty members and plans to roll out a similar program for the liquor business [41]

TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced that it has rescheduled its November 6, 2025 earnings conference call to discuss the results for the third quarter ended September 30, 2025. The call will still be held on Thursday, November 6, 2025, but will take place at 8:30 a.m. Eastern Time. The Company will report its financial results for the third quarter 2025 on the same d ...

Core Viewpoint - Tilray Brands has seen a 20% increase in stock value this year, marking a significant turnaround after years of decline, driven by renewed expectations for marijuana reform in the U.S. [1][2] Company Performance - Despite the current year's positive performance, Tilray's stock has plummeted 99% over the past seven years, with a market cap dropping from nearly $42 billion in 2018 to under $2 billion today [5]. - In the most recent fiscal year ending May 31, Tilray reported net revenue of $821.3 million, a 4% year-over-year increase, although its cannabis business declined by 9% [7]. Market Conditions - The Canadian cannabis market has become saturated, while the U.S. market remains inaccessible due to federal restrictions, limiting growth opportunities for Canadian producers like Tilray [6]. - The hope for U.S. cannabis reform, including potential rescheduling from Schedule I to Schedule III, has generated optimism among investors [10]. Valuation and Investment Appeal - Tilray's current price-to-sales ratio is below 1.8, suggesting it may be undervalued, making it an attractive option for investors looking for bargains [11]. - The diversification into alcohol has provided some stability, although the cannabis segment's performance remains weak [11].

Group 1 - The U.S. stock market showed interest in Tilray Brands, with shares rising by 5%, outperforming the S&P 500 index which increased by 0.4% [1] - Stock prices of marijuana companies like Tilray often react positively to medical testing results or movements towards legalization [2] - A study from researchers at the University of Georgia and University of Colorado indicated that states with lenient cannabis laws saw a significant reduction in opioid prescriptions, with an average decline of 16% and some states reaching 22% [3][4] Group 2 - The findings from the study support the argument for cannabis as a beneficial treatment, which could encourage politicians to reform federal laws prohibiting it, potentially improving the fortunes of Tilray and the cannabis industry [5] - New research suggests that legalized cannabis could replace harmful opioids, strengthening the case for its de facto legalization [6] - The Motley Fool Stock Advisor analyst team has identified 10 stocks they believe are better investment options than Tilray Brands [7]

Market Overview - Pre-market earnings are flat-to-down, with the Dow down 16 points, S&P 500 up 1 point, and Nasdaq down 4 points, while the small-cap Russell 2000 is down 2 points [1] Employment Data - Weekly Jobless Claims numbers are absent for the second consecutive week; the last reported figure showed a drop from 264K to 218K, a decrease of 46K [2] - Continuing Claims have stabilized around 1.93 million, below the 13-week range of 1.94-1.975 million [2] Retail Sector Insights - CNBC's NRF Retail Monitor report for September indicates a decline in retail and restaurant sales by 0.7%, following a 0.5% increase in August; core retail sales also fell by 0.5% from a previous increase of 0.3% [3][4] - The year-over-year growth for retail sales has decreased to 5.4% for headline and 5.7% for core, down from 6.8% and 6.7% respectively a month ago, indicating a healthy spending level despite the recent declines [4] Q3 Earnings Reports - Delta Air Lines reported Q3 earnings of $1.71 per share, exceeding the $1.52 analysts' expectations, with revenues of $16.67 billion, surpassing the Zacks consensus by 5.61% and up from $15.68 billion year-over-year [5][6] - Delta has raised its Q4 earnings guidance to a range of $1.60-1.90 per share, leading to an 8% increase in shares during pre-market trading [6] - PepsiCo reported Q3 earnings of $2.29 per share, slightly above consensus estimates, with revenues of $23.94 billion, outperforming expectations by 0.25%; however, shares are down 8% year-to-date [7] - Tilray reported fiscal Q1 earnings of $0.00 per share, exceeding expectations of -$0.03, with revenues of $210 million, up from anticipated $206.8 million; non-medical cannabis revenues increased by 12% year-over-year, resulting in an 18% rise in shares during pre-market activity [8]

Core Insights - Tilray Brands Inc. (NASDAQ:TLRY) experienced a significant increase in share price, rising by 8.23% to $1.71, as investors adjusted their portfolios in anticipation of a decision from President Donald Trump regarding the legalization of cannabis and CBD products [1][3]. Group 1: Market Reaction - Investors are actively investing in cannabis product manufacturers, including Tilray Brands Inc., Canopy Growth, Cronos Group, and Aurora Cannabis, in light of a positive decision expected soon [2]. - The rise in Tilray's stock price reflects broader market optimism surrounding potential cannabis legalization, driven by Trump's recent promotion of cannabis and CBD for medical use [3]. Group 2: Policy Implications - Trump's social media video highlighted the potential benefits of CBD oil, suggesting it could transform senior healthcare and reduce medical costs in the U.S. by $64 billion, which has influenced investor sentiment [3].

Core Insights - The cannabis industry is experiencing renewed investor interest due to potential reform discussions in the U.S. government [2][5] - Despite recent rallies, cannabis stocks have significantly underperformed compared to broader market indices over the past five years [1][7] Group 1: Industry Overview - Cannabis remains illegal at the federal level in the U.S., complicating operations for companies that wish to operate across state lines [3] - Companies like Tilray, which are based in Canada, face legal barriers to entering the U.S. market, limiting their growth potential [4] Group 2: Potential for Reform - Discussions about rescheduling cannabis from a Schedule I to a Schedule III substance could lead to increased research opportunities and lower tax burdens for cannabis companies [5][6] - Rescheduling could serve as a precursor to full legalization, which many investors believe would significantly benefit the industry [6] Group 3: Market Valuation - Cannabis stocks, including Tilray Brands, are currently trading at attractive valuations, with Tilray's market cap at approximately $1.8 billion, down from nearly $17 billion in early 2021 [8] - The stock trades at 1.8 times its trailing sales and a price-to-book multiple of 1.2, indicating heavy discounting by investors due to industry uncertainties [9] Group 4: Investment Considerations - While there is excitement around potential cannabis reform, historical context suggests that previous reform discussions have not led to substantial changes [10][11] - Long-term investment in cannabis stocks may be suitable for high-risk tolerance investors, but a cautious approach is recommended for the majority [12]

Core Insights - TerrAscend Corp. will host a conference call to discuss its third quarter results for the period ending September 30, 2025, scheduled for November 6, 2025, at 5:00 p.m. Eastern Time [1] Group 1: Conference Call Details - The conference call will take place on Thursday, November 6, 2025 [2] - Dial-in number for the call is 1-888-510-2154, with a replay available until midnight Eastern Time on November 20, 2025 [2] - The replay entry code for the call is 73897 [2] Group 2: Company Overview - TerrAscend is a leading cannabis company listed on TSX, with operations in Pennsylvania, New Jersey, Maryland, Ohio, and California [3] - The company operates retail locations such as The Apothecarium and has scaled cultivation, processing, and manufacturing facilities [3] - TerrAscend offers a diverse product selection for both medical and legal adult-use markets, owning or licensing several brands including Cookies, Lemonnade, and Wana [3]

Core Insights - Green Thumb Industries Inc. has opened its 108th cannabis retail location and started generating revenue from its four dispensaries in Minnesota, which is expected to contribute to increased revenues for the company [1]. Company Developments - The opening of the new retail location marks a significant milestone for Green Thumb Industries, expanding its footprint in the cannabis market [1]. - The revenue generation from the Minnesota dispensaries, although described as minor, is anticipated to positively impact the company's overall financial performance [1]. Industry Context - The cannabis sector continues to see growth with companies like Green Thumb Industries expanding their retail presence, indicating a robust market environment [1].

Core Insights - Tilray Brands' shares have surged approximately 300% since July, driven by optimism surrounding potential cannabis reform in the U.S. [1][6] - The upcoming earnings report on October 9 could serve as a catalyst for further stock movement, depending on the company's financial performance [2][4] Financial Performance - For the fiscal year ending May 31, Tilray reported net revenue of $821.3 million, a 4% year-over-year increase, although its core cannabis business saw a 9% decline, with sales dropping to $249 million [5] - Despite recent stock gains, Tilray's overall performance has been poor, with a 65% decline in stock value over the past five years [3][6] Market Challenges - The competitive landscape of the Canadian cannabis market poses significant challenges for Tilray and other producers, often leading to disappointing earnings reports [4][6] - The company's financial struggles and reliance on acquisitions to diversify revenue streams highlight ongoing vulnerabilities in its business model [7]